The Association between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model

American Journal of Epidemiology

Volumn 184, Issue 9, 2016, Pages 681-689

  Sadatsafavi, Mohsen ^a,b   Sin, Don D ^a,c   Zafari, Zafar ^a,b   Criner, Gerard ^d   Connett, John E ^e   Lazarus, Stephen ^f   Han, Meilan ^g   Martinez, Fernando ^h   Albert, Richard ⁱ  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

chronic obstructive pulmonary disease; nonlinear mixed models; random effects; randomized trials; survival analysis

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; GLUCOCORTICOID; PLACEBO; ANTIINFECTIVE AGENT;

ANTIBIOTICS; DISEASE SEVERITY; HEALTH SURVEY; INDIVIDUAL VARIATION; NONLINEARITY; NUMERICAL MODEL; RESPIRATORY DISEASE; SOFTWARE; SURVIVAL;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DATA ANALYSIS SOFTWARE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OXYGEN THERAPY; PARAMETRIC TEST; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; UNITED STATES; COMPLICATION; DISEASE COURSE; MULTICENTER STUDY (TOPIC); NORTH AMERICA; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

CANADA; UNITED STATES;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DISEASE PROGRESSION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NORTH AMERICA; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84994420242     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kww085     Document Type: Article

References (31)

1. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002; 121(5 suppl):121S-126S.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171.
3. Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and nationwide emergency department sample 2006-2011. Chest. 2015; 147(4):989-998.
4. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-365.
5. Canadian Thoracic Society. The Human and Economic Burden of COPD: A Leading Cause of Hospital Admission in Canada. Ottawa, ON, Canada: Canadian Thoracic Society; 2010. http://www.respiratoryguidelines.ca/sites/all/files/CTS- COPD-report.pdf. Accessed September 22, 2015.
6. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327(20): 1420-1425.
7. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
8. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008; 177(1):19-26.
9. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 suppl 2): 398S-401S.
10. Mittmann N, Kuramoto L, Seung SJ, et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. 2008;102(3):413-421.
11. Cox C, Chu H, Schneider MF, et al. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med. 2007;26(23):4352-4374.
12. Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1(3):255-273.
13. Littell RC, ed. SAS for Mixed Models. 2nd ed. Cary, NC: SAS Press; 2011.
14. Bellamy SL, Li Y, Ryan LM, et al. Analysis of clustered and interval censored data from a community-based study in asthma. Stat Med. 2004;23(23):3607-3621.
15. Aaron SD. Management and prevention of exacerbations of COPD. BMJ. 2014;349:g5237.
16. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365(8):689-698.
17. Berridge DM, Whitehead J. Analysis of failure time data with ordinal categories of response. Stat Med. 1991;10(11): 1703-1710.
18. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s-53s.
19. Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24(6): 682-701.
20. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1):293-298.
21. Kelly PJ, Lim LL. Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med. 2000;19(1):13-33.
22. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Parzen E, Tanabe K, Kitagawa G, eds. Selected Papers of Hirotugu Akaike. New York, NY: Springer Publishing Company; 1998:199-213.
23. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons, Inc.; 2002.
24. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321-1327.
25. Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. Br J Cancer. 2004; 91(7):1229-1235.
26. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
27. Xue X, Brookmeyer R. Bivariate frailty model for the analysis of multivariate survival time. Lifetime Data Anal. 1996;2(3):277-289.
28. Yan J, Fine JP. Analysis of episodic data with application to recurrent pulmonary exacerbations in cystic fibrosis patients. J Am Stat Assoc. 2008;103(482):498-510.
29. Fine JP, Yan J, Kosorok MR. Temporal process regression. Biometrika. 2004;91(3):683-703.
30. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 179(5):369-374.
31. Sadatsafavi M, Fitzgerald JM. Heterogeneity's ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations. Thorax. 2014; 69(11):1043-1044.